Baligh Yehia, MD
Welcome
.......................................................................................................................................................................................................................................
Dr. Baligh Yehia is a physician working at the intersection of clinical medicine, research, and public policy. He aspires to find sustainable solutions for improving patient care and our nation's healthcare system. Over the course of his career, Dr. Yehia has focused on reducing health disparities, promoting health equity, and improving the quality of healthcare delivery. He is dedicated to advancing the profession of medicine and has held top leadership positions in national professional organizations. Follow Dr. Yehia on twitter and contact him for additional information on his research.
News
"Helping patients with HIV stay in care is a key way to reduce their chances of getting sick from their disease and prevent the spread of HIV in the community," study author Dr. Baligh Yehia, a fellow in the division of infectious disease and the health policy research program at Penn Medicine. "Our findings show that too many patients are falling through the cracks."
promoting equity & quality in healthcare
Despite antiretroviral medication errors being a common occurrence upon hospital admission among patients with HIV, they are typically corrected within 48 hours, according to study findings published in Clinical Infectious Diseases. The study was led by Baligh Yehia, M.D.
The proportion of U.S. patients who receive effective treatment has jumped from 45% in 2001 to 72% in 2010, according to a study published in JAMA, but that's still lower than some previous estimates. There is no denying the progress we have made over the past decade,” lead study author Baligh Yehia told reporters. “But more resources and new technology are needed to ensure that more patients have access to HIV therapy and obtain the full benefits of these drugs,” he said.
A nonprofit HIV/AIDS advocacy and care organization is waging a public campaign to pressure Gilead to exercise restraint in setting the initial price for the so-called "Quad" pill. Baligh Yehia, an infectious-disease specialist at the University of Pennsylvania, said the Quad appears to mitigate certain side effects versus Atripla, but provides no significant advantage in efficacy.
